Physician profile
James Callis
NPI 1316942295
$1,149.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $344 · 2021: $274 · 2022: $29.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $385.75 | 2019 | |
| Endologix LLC | $334.02 | 2020-2021 | |
| Medtronic, INC. | $136.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $76.50 | 2019-2020 | |
| Biocompatibles, INC. | $48.09 | 2019 | |
| Boston Scientific Corporation | $41.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.50 | 2019-2022 | |
| Silk Road Medical, INC. | $27.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.22 | 2020 | |
| Amarin Pharma, INC. | $18.52 | 2019 | |
| Urovant Sciences INC | $14.65 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Callis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.